News Novartis sheds MorphoSys staff, sites after pelabresib delay Novartis has confirmed it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, by the end of next year.
News Editas axes two-thirds of its staff, including its CMO Editas Medicine ends development of its gene-editing therapy for thalassaemia and sickle cell, shedding 65% of staff and narrowing its R&D focus.
News Mulvany hits the reset button at BenevolentAI The shape of BenevolentAI following the return of co-founder Ken Mulvany has started to crystallise and could see the company return to private hands.
News Alligator slashes workforce and pares down its pipeline Faced with a cash crunch, Alligator Biosciences has said it plans to shed up to 70% of its workforce.
News Medigene axes staff and refocuses its TCR pipeline Medigene slashes staff and delays trials of its lead TCR therapy candidate as it refocuses its pipeline
News 23andMe ends drug development and slashes staff 23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.
News Lilly grabs first-ever FDA nod for a sleep apnoea drug Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea, which affects millions in the US.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.